Efavirenz

Chemical formula: C₁₄H₉ClF₃NO₂  Molecular mass: 315.675 g/mol  PubChem compound: 64139

Therapeutic indications

Efavirenz is indicated for:

Human immunodeficiency virus type 1 infection

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Efavirenz is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected adults, adolescents and children 3 years of age and older.

Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts <50 cells/mm³, or after failure of protease inhibitor (PI) containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after failure of regimens containing efavirenz.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Efavirenz is contraindicated in the following cases:

Terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, ergot alkaloids

at least one of
Terfenadine
Astemizole
Cisapride
Midazolam
Triazolam
Pimozide
Bepridil
Ergot alkaloids

Severe hepatic impairment

Hepatic failure stage IV

St. John's wort (Hypericum perforatum)

Hypericum perforatum (St John's Wort)

Drugs that are known to prolong the QTc interval (proarrhythmic)

Drugs prolonging QT interval

Family history of sudden death, QT prolongation

at least one of
Family history of sudden death
Prolonged QT interval
Long QT syndrome
Family history of long QT syndrome
Risk factors that increase the risk of QT prolongation

Cardiac arrythmias, bradycardia, congestive cardiac failure

at least one of
Arrhythmia
Congestive heart failure

Disturbances of electrolyte balance

Electrolyte imbalance

Elbasvir/grazoprevir

Elbasvir and grazoprevir

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: STOCRIN Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈